title: De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.
abstract: BACKGROUND
  Advagraf is a new modified-release once-daily formulation of tacrolimus with a similar efficacy and safety profile to twice-daily tacrolimus (Prograf) according to clinical trials. Few data are published about its use in clinical practice, outside of sponsored clinical trials. We compared efficacy and basic pharmacokinetics of once-daily and twice-daily tacrolimus in de novo renal transplantation.
  
  
  METHODS
  The Advagraf group included 26 de novo renal cases who had received initial immunosuppression with once-daily tacrolimus (0.2 mg/kg from day 1 posttransplantation) combined with mycophenolic acid, steroids, and anti-CD25 monoclonal antibodies (2 doses). We compared them with a Prograf group of 26 transplants performed immediately before, who received equivalent immunosuppression with twice-daily tacrolimus (0.2 mg/kg from day 1).
  
  
  RESULTS
  We did not observe significant differences between groups in demographics, efficacy, and basic pharmacokinetics, namely, tacrolimus trough levels at 7, 15, 30, 60, or 90 days. We found that recipients on Advagraf needed significantly higher tacrolimus doses per kg up to 6 months post-transplantation than those on Prograf: 0.16 vs 0.11; 0.14 vs 0.08; and 0.12 vs 0.08 mg/kg at 1, 3, and 6 months. No patient suffered severe liver dysfunction. There were no differences between groups in the administration of drugs interacting with CYP3A4 or prokinetics, which could alter tacrolimus pharmacokinetics.
  
  
  CONCLUSIONS
  Among de novo renal cases, the new once-daily formulation of tacrolimus offered a similar short-term efficacy profile as the twice-daily tacrolimus. But it was necessary to use up to a 50% higher dose of Advagraf than Prograf to achieve similar trough levels during the first 6 months.
authors.affiliation: Department of Nephrology, Hospital del Mar, Barcelona, Spain. mcrespo@imas.imim.es
authors.forename: M
authors.initials: M
authors.lastname: Crespo
authors.forename: M
authors.initials: M
authors.lastname: Mir
authors.forename: M
authors.initials: M
authors.lastname: Marin
authors.forename: S
authors.initials: S
authors.lastname: Hurtado
authors.forename: C
authors.initials: C
authors.lastname: Estadella
authors.forename: X
authors.initials: X
authors.lastname: Gurí
authors.forename: O
authors.initials: O
authors.lastname: Rap
authors.forename: R
authors.initials: R
authors.lastname: Moral
authors.forename: J M
authors.initials: JM
authors.lastname: Puig
authors.forename: J
authors.initials: J
authors.lastname: Lloveras
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000097:blood; D004305:Dose-Response Relationship, Drug; D000068338:Everolimus; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D053645:Interleukin-2 Receptor alpha Subunit / Q000276:immunology; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D012086:Reoperation / Q000706:statistics & numerical data; D012189:Retrospective Studies; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016559:Tacrolimus / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D053645:Interleukin-2 Receptor alpha Subunit; D000068338:Everolimus; D020123:Sirolimus; D016559:Tacrolimus